Thomas Cahill, M.D., Ph.D.
Founder and Managing Partner, Newpath Partners
Dr. Cahill is the Founder and Managing Partner of Newpath Partners, a Boston based life science venture fund focused on building therapeutic companies around transformational scientific discoveries. Newpath is a founding investor in most of their life science companies and focuses on uniquely aligning interests between academic scientists, investors and management teams. Dr. Cahill is directly involved as either a Director or Observer in the following companies: Myeloid Therapeutics, Prime Medicine, Chroma Medicine, Kisbee Therapeutics, Kojin Therapeutics, Exo Therapeutics, and YourBio Health. In addition, Dr. Cahill is involved with non-profit and non-partisan groups such as Scientists to Stop COVID-19 (STSC-19) and the Personal Genetics Education Project (pgEd). Dr. Cahill received both his M.D. and Ph.D. from Duke University.